Inhaled therapy reduces morning dips in asthma

Area of Science:

• Respiratory Medicine
• Clinical Pharmacology

Background:

• Nocturnal asthma symptoms and morning dips in peak expiratory flow rate (PEFR) significantly impact patient quality of life.
• Optimizing inhaled therapies is crucial for managing asthma control and reducing diurnal variations in lung function.

Purpose of the Study:

• To evaluate the efficacy of regular inhaled salbutamol and beclomethasone dipropionate in improving mean PEFR and reducing morning dips in asthmatic patients.
• To compare the effects of inhaled beta-agonist monotherapy versus combination therapy with inhaled corticosteroids.

Main Methods:

• A cohort of 14 asthmatic patients with nocturnal symptoms and morning PEFR dips received sequential treatment.
• Initial treatment involved regular inhaled salbutamol for 1-2 weeks, followed by the addition of inhaled beclomethasone dipropionate for 2 weeks.

Main Results:

• Mean PEFR normalized in 13 out of 14 patients.
• Significant reduction in morning PEFR dips was observed in 8 patients.
• Inhaled salbutamol alone improved PEFR and reduced dips in responsive patients; inhaled steroids provided further improvement.
• In the non-responsive subgroup, inhaled steroids were primarily responsible for the improvement in mean PEFR.

Conclusions:

• Regular inhaled therapy, including beta-agonists and corticosteroids, is effective in improving lung function and mitigating diurnal PEFR variations in asthma.
• This inhaled treatment strategy offers a safe and effective alternative to oral agents for managing persistent asthma symptoms.
• Individualized responses to inhaled therapies highlight the importance of tailored treatment approaches in asthma management.